Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Haemophilia treatment in 2030

View through CrossRef
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as well as dilemmas. Today, the issue of inhibitors overshadows the entire haemophilia community together with lack of treatment for large parts of the world's persons with haemophilia.AimsThe aim of this paper was to provide a perspective on haemophilia treatment in 2030 and its provenance.MethodsLiterature review on history, treatment of haemophilia today as well as of emerging therapies give a base for the author's opinion on haemophilia treatment in 2030.ResultsDevelopment of haemophilia treatment has virtually exploded during the last decade and a number of new clotting factor concentrates and alternative approaches are in the pipeline.ConclusionThe collection of treatment resources that we can see on the horizon gives hope that each person with haemophilia will get the care needed in 2030. The products used will be directed by individual needs and tailored to regional and local situations.
Title: Haemophilia treatment in 2030
Description:
IntroductionLooking into the future is difficult and sometimes hazardous.
A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as well as dilemmas.
Today, the issue of inhibitors overshadows the entire haemophilia community together with lack of treatment for large parts of the world's persons with haemophilia.
AimsThe aim of this paper was to provide a perspective on haemophilia treatment in 2030 and its provenance.
MethodsLiterature review on history, treatment of haemophilia today as well as of emerging therapies give a base for the author's opinion on haemophilia treatment in 2030.
ResultsDevelopment of haemophilia treatment has virtually exploded during the last decade and a number of new clotting factor concentrates and alternative approaches are in the pipeline.
ConclusionThe collection of treatment resources that we can see on the horizon gives hope that each person with haemophilia will get the care needed in 2030.
The products used will be directed by individual needs and tailored to regional and local situations.

Related Results

Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Summary.  Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey (PPS) investigated current trends in haemophilia trea...
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
A transgender person with haemophilia
A transgender person with haemophilia
Abstract Introduction Transgender people face many obstacles to accessing healthcare but cultural changes are likely to i...
Haemophilia care in Iraq; a multi-centre study
Haemophilia care in Iraq; a multi-centre study
Objectives: To evaluate the level of care available to haemophilia patients. Method: The descriptive, retrospective analytical study was conducted from December 15, 2020, to March...
Normalisation of Haemostasis in Haemophilia A
Normalisation of Haemostasis in Haemophilia A
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, ...
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
IntroductionCoagulation products have allowed patients with severe haemophilia to lead a normal life. This is, however, only true for patients who received an early diagnosis and c...
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
AbstractIntroduction2022 was a landmark year with two adeno‐associated viral vectors (AAVs) receiving conditional marketing authorization from EMA for the treatment of persons with...

Back to Top